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Abstract
In lammatory	 breast	 cancer	 (IBC)	 is	 the	 most	 aggressive	 form	 of	 this	 tumor,	 with	 the	 clinical	 and	
biological	characteristics	of	a	rapidly	proliferating	disease.	This	tumor	is	always	diagnosed	at	advanced	
stages,	atleast	stage	IIIB	(locally	advanced),	so	its	management	requires	an	integrated	multidisciplinary	
approach	with	a	systemic	therapy	followed	by	surgery	and	radiation	therapy.	Patients	with	IBC	usually	
have	 a	 worse	 prognosis	 but	 the	 achievement	 of	 a	 pathologic	 complete	 response	 after	 neoadjuvant	
chemotherapy	may	have	good	rates	of	overall	survival.	We	present	the	case	of	a	47	year	old	women	with	
IBC,	luminal	B	and	with	high	proliferative	index;	she	was	successfully	treated	with	a	sequential	schedule	
of	 chemotherapy	 (anthracyclines	 dose-dense/carboplatin+	 taxane/Cyclophosphamide	 Methotrexate	
Fluorouracil),	hormone-therapy,	complementary	radiotherapy	and	 inally	surgery	until	the	achievement	
of	a	complete	clinical	and	pathological	response.
Luminal	 B	 in lammatory	 breast	 cancer	 with	 high	 proliferation	 index	 can	 bene it	 from	 sequential	
schedules	of	neoadjuvant	chemotherapy	and	hormonal	treatment	and	this	can	result	 in	pathological	
complete	response.
Introduction
	 Locally	advanced	inoperable	breast	cancer	includes	stages	IIIB	(T4a	involves	the	chest	wall,	T4b	
involves	 the	 skin,	 T4c	 involves	 the	 chest	 wall	 and	 the	 skin),	 stages	 IIIC	 (N3	 with	 any	 T)	 and	 the	
in lammatory	 carcinoma	 or	 carcinomatous	 mastitis	 (T4d).	 In lammatory	 breast	 cancer	 (IBC)	 is	
characterized	by	a	diffuse	hardening	of	the	skin	of	the	breast,	a	rapid	onset	of	erythema,	edema	and	
peaud'orange,	with	or	without	an	underlying	palpable	mass	[1-3].	IBC	usually	develops	at	younger	ages	
than	the	other	breast	cancers	and	it	is	atleast	stage	IIIB	(locally	advanced).	The	management	of	locally	
advanced	IBC	requires	an	integrated	multidisciplinary	approach	with	a	 irst	systemic	therapy	followed	by	
surgery	and	radiation	therapy	[1-3].	This	type	of	tumor	usually	has	a	poor	prognosis	and	a	high	risk	of	
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Abbreviations
IBC:	in lammatory	breast	cancer;	pCR:	pathologic	complete	response;	ER:	estrogen	receptor;	PR:	
progesterone	receptor;	HER2:	human	epidermal	growth	factor	receptor	2;	CA:	cancer	antigen;	CEA:	
carcino-embryonic	antigen;	CT:	computed	tomography;	G-CSF:	granulocyte	colony-stimulating	factor;	
CMF:	 luteinizing	hormone-releasing	hormone;	Cyclophosphamide/Methotrexate/Fluorouracil;	LHRH:	
MRI:	magnetic	resonance	imaging;	DIEP:	 ;	G:	grade.deep	inferior	epigastric	perforator
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local	recurrence	and	of	metastases.	Accounting	for	approximately	10–15 %	of	locally	advanced	breast	
cancer,	patients	with	IBC	have	5-year	overall	survival	rates	of	34%	to	47%	[4].	Distant	metastases	are	
detected	at	the	time	of	diagnosis	in	about	4 %	of	all	breast	cancer	patients,	but	are	observed	in	14 %	of	T3	
and	in	26 %	of	T4	patients	with	IBC	[5].
	 There	is	no	standard	chemotherapy	regimen	for	IBC,	usually	patients	receive	the	following	setting	
of	adjuvant	chemotherapy:	combined	or	sequential	anthracyclines	and	taxanes	for	at	least	6-8	cycles.	This	
chemotherapy	regimen	has	been	associated	with	higher	rate	of	pathologic	complete	response	(pCR)	and	
better	survival	outcome,	compared	with	other	agents	[6].
	 Many	studies	on	neoadjuvant	therapy	included	heterogeneous	population	of	patients	with	breast	
cancer	with	different	biological	characteristics,	but	only	few	patients	with	IBC.	The	addition	of	a	platinum	
compound	(carboplatin)	to	neoadjuvant	chemotherapy	demonstrated	an	increase	in	pCR	rate	in	triple-
negative	IBC	[7].
Case	Presentation
	 We	present	the	case	of	a	47	year	old	women	with	a	bilateral	in lammatory	breast	cancer:	right	
breast	 showed	 tough	 and	necrotic	 skin,	 ulcerated	 in	 the	outer	quadrants,	with	nipple	 retracted	 and	
axillary	lymph	node	package;	left	breast	had and	lymphadenopathy.peaud'orange	
	 A	diagnostic	mammogram	and	ultrasound	analysis	showed	a	widespread	structural	alteration	in	
the	right	breast,	with	an	appearance	grossly	pseudo-nodular	at	the	level	of	the	axillary	extension	cable	
(diameter	24mm);	at	the	same	time	a	diagnostic	mammogram	showed	a	nodular	lesion	(diameter	7	mm)	
in	the	upperouterquadrant	of	the	leftbreast,	furthermore	an	axillary	adenopathy	was	evident	(diameter	
17mm)	in	the	left	breast.
	 Core	biopsy	analysis	of	left	breast	lesion	diagnosed	an	invasive	ductal	breast	carcinoma,	grade	
G3,immunohistochemistry	indicated	estrogen	receptor	(ER)	90%	positive,	progesterone	receptor	(PR)	
60%	positive,	ki67	60%	positive,	human	epidermal	growth	factor	receptor	2	(HER2)	negative,	with	the	
classi ication	of	luminal	B.	A	core	needle	biopsy	of	lateral	and	contra	lateral	axillary	lymph	nodes	was	
performed	revealing	metastatic	repetition.	Core	biopsy	of	right	breast	was	not	performed.	Plasma	tumor	
markers	were	evaluated:	cancer	antigen	(CA)	15-3	was	31,	8	U/mL	and	carcino-embryonic	antigen	(CEA)	
was	2.6	ng/mL.	Computed	tomography	(CT)	scan	showed	no	evidence	of	metastatic	disease	outside	of	the	
breast	and	of	the	axillae,	con irming	a	locally	advanced	IBC	(cT4d,	cN2).
	 Core	biopsy	analysis	of	left	breast	lesion	diagnosed	an	invasive	ductal	breast	carcinoma,	grade	
G3,immunohistochemistry	indicated	estrogen	receptor	(ER)	90%	positive,	progesterone	receptor	(PR)	
60%	positive,	ki67	60%	positive,	human	epidermal	growth	factor	receptor	2	(HER2)	negative,	with	the	
classi ication	of	luminal	B.	A	core	needle	biopsy	of	lateral	and	contra	lateral	axillary	lymph	nodes	was	
performed	revealing	metastatic	repetition.	Core	biopsy	of	right	breast	was	not	performed.	Plasma	tumor	
markers	were	evaluated:	cancer	antigen	(CA)	15-3	was	31,	8	U/mL	and	carcino-embryonic	antigen	(CEA)	
was	2.6	ng/mL.	Computed	tomography	(CT)	scan	showed	no	evidence	of	metastatic	disease	outside	of	the	
breast	and	of	the	axillae,	con irming	a	locally	advanced	IBC	(cT4d,	cN2).
	 The	 patient	 underwent	 neoadjuvant	 chemotherapy	 consisting	 of	 Epirubicin	 90	 mg/mq	 and	
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Cyclophosphamide	 600	 mg/mq	 p1q15	 with	 granulocyte	 colony-stimulating	 factor	 (G-CSF)	 as	
prophylaxis	of	chemotherapy-induced	febrile	neutropenia.	After	four	cycles	of	chemotherapy	the	patient	
achieved	a	partial	response	(50%)	determined	by	clinical	and	instrumental	examination. The	patient		
then	received	four	cycles	of	chemotherapy	with	carboplatin	AUC2	and	Paclitaxel	80	mg/mq	p1,8,15	q28,	
followed	by	additional	clinical	response.
	 Considered	the	extent	of	the	disease,	the	excellent	response	to	chemotherapy	and	the	good	patient	
compliance,	 another	 3	 cycles	 of	 chemotherapy	 were	 performed,	 according	 to	 the	 scheme	
Cyclophosphamide/Methotrexate/Fluorouracil	(CMF)	p1,8	q28,	which	 inished	on	March	2015	with	low	
grade	(G)	of	toxicity	and	a	complete	clinical	response	of	the	patient.	The	adverse	events	described	by	the	
patients	were	the	following:	anemia	G1,	neutropenia	G1	and	alopecia	G4.
	 A	diagnostic	mammogram	of	the	right	and	left	breast	was	performed	on	April	2015	and	showed	
only	an	increase	in	density	of	the	right	breast	and	CT	scan	was	negative.	The	patient	received	endocrine	
therapy	with	Letrozole	and	luteinizinghormone-releasinghormone	(LHRH)	agonist	with	no	toxicity	in	
the	patient.	A	magnetic	resonance	imaging	(MRI)	performed	on	June	2015	showed	complete	radiologic	
response	 to	 treatment.	 Radical	 right	 breast	 mastectomy	 and	 axillary	 lymph	 node	 dissection	 were	
performed	on	October	2015,	together	to	right	breast	reconstruction	with	micro	vascular	deep	inferior	
epigastric	perforator	(DIEP)	 lap.	At	the	same	time,	the	patient	underwent	left	quadrantectomy	with	left	
sentinel	node	control	plus	remodeling	of	left	breast.	Complementary	radiotherapy	was	done	to	the	left	
breast	to	a	total	dose	of	66Gy	and	didn't	determine	any	toxicity.	The	histopathologicalanalysis	of	the	right	
breast	tissue	indicated	the	presence	of	single	regressive	tumor	cells	with	the	following	characteristics:	ER	
90%,	PgR	1%,	ki67	3%,	HER2	negative;	no	cancer	cells	were	observed	in	the	lymph	nodes.	Left	breast	and	
left	sentinel	node	showed	no	evidence	of	residual	carcinoma.	These	data	demonstrated	a	pathological	
complete	response	of	the	patient.	Our	patient	is	actually	free	of	disease,	and	she	is	continuing	hormonal	
treatment	with	aromatase	inhibitors	without	side	effects.
Discussion
	 In lammatory	breast	cancer	is	extremely	rare	and	more	aggressive	than	the	other	types	of	breast	
cancer.	The	risk	of	contralateral	breast	cancer	following	IBC	is	rare,	there	were	only	few	case	reports	of	
bilateral	IBC	reported	in	the	literature	[8],	in	fact	the	tumor	here	described	is	the	only	case	followed	by	our	
Department.
	 Nowadays,	 primary	 systemic	 treatment	 is	 considered	 the	 standard	 of	 care	 for	 breast	 cancer	
patients	with	locally	advanced	and	in lammatory	breast	cancer.	Stage	III	IBC	is	often	characterized	by	a	
worse	 prognosis	 than	 stage	 III	 non-in lammatory	 tumors,	 with	 increased	 loco-regional	 and	 distant	
recurrence	rates	[9,	10].	 	Although	the	risk	of	contralateral	breast	cancer	following	IBC	is	rare	[8],	our	
patient	presented	a	bilateral	IBC.
	 The	 standard	 treatment	 of	 IBC	 consists	 of	 neo-adjuvant	 chemotherapy	 followed	 by	modi ied	
radical	 mastectomy,	 radiotherapy	 or	 chemo-radiotherapy	 and	 eventually	 endocrine	 therapy,	 when	
appropriate	 [11,	12].	A	pCR	after	neo-adjuvant	 chemotherapy	has	been	consistently	associated	with	
improved	outcomes	and	bene it	in	terms	of	overall	survival	[13],	regardless	of	biological	breast	cancer	
subtype;	our	patient	developed	a	good	response	after	neo-adjuvant	chemotherapy.	
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Unfortunately,	despite	the	progress	 in	breast	cancer	treatment,	 the	survival	of	patients	with	IBC	still	
remains	at	low	rates,	with	a	5-year	overall	survival	of	46%	and	a	disease-free	survival	of	40%	[14].		On	the	
contrary,	our	experience	demonstrated	that	the	presented	case	of	luminal	B	in lammatory	breast	cancer	
with	 high	 proliferation	 index	 bene itted	 from	 sequential	 schedules	 of	 chemotherapy	 and	 hormonal	
treatment.	Our	patient	obtained	a	pathological	complete	response	after	less	than	1	year	of	treatment,	
without	affecting	her	quality	of	life,	very	rare	for	a	bilateral	in lammatory	breast	cancer.
	 Our	 patient	 achieved	 an	 excellent	 result	 with	 chemotherapy,	 using	 the	 most	 active	 drugs	
(anthracycline	and	taxane)	but	with	a	peculiar	schedule	that	ensures	a	good	tolerability.	In	fact	the	only	
observed	 toxicities	were	 low,	 the	 only	 severe	 toxicity	was	 alopecia	 G4.	 The	 haematological	 toxicity,	
usually	caused	byanthracycline,	was	avoided	thanks	to	colony	stimulating	factors.
	 Our	patient	responded	very	well	with	a	high	chemosensitivity	to	the	therapy,	therefore	further	
sequential	 chemotherapy	 schemes	were	 performed	 and	 led	 to	 a	 clinical	 and	 instrumental	 pCR.	 The	
subsequent	endocrine-therapy	consolidated	the	results	and	 inally	the	surgery	response	was	excellent.	
Due	 to	 the	 optimal	 response	 after	 antracycline	 and	 taxanes,	 we	 have	 chosen	 to	 treat	 our	 patient	
sequentially	 with	 CMF	 schedule,	 since	 a	 large	 trial	 demonstrated	 ef icacy	 of	 CMF	 for	 IBC,	 with	 an	
improvement	 of	 8-15%	 of	 the	 10-year	 overall	 survival	 by	 the	 addition	 of	 CMF	 to	 radiotherapy	 and	
tamoxifen	[15].	Other	trials	showed	that	adding	anthracyclines	and	taxanes	led	an	increase	of	the	5-year	
survival	of	about	70 %	for	locally	advanced	cancer	and	of	about	40 %	for	IBC	[14,	16].
	 Our	patient	was	HER2	negative,	so	she	has	not	been	treated	with	target	therapy,	but	has	obtained	a	
pCR	only	with	chemotherapy	and	hormonal	therapy,	accordingly	with	her	molecular	phenotype.	Our	
patient	is	still	free	of	disease,	and	she	is	continuing	only	hormonal	treatment	with	aromatase	inhibitors	
without	side	effects.
Figures
Figure	1:	Images	of	starting	point	of	right	breast	(A-B)	and	of	 inal	result	(C)	of	breast	from	a	case	of	in lammatory	
breast	cancer.
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Conclusion
	 In	conclusion	our	patient	obtained	a	pathological	complete	response	after	 less	 than	1	year	of	
treatment,	without	affecting	her	quality	of	life	and	with	an	optimal	esthetic	effect,	very	rare	for	a	bilateral	
in lammatory	breast	cancer.
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